We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+43.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.56B
AUM Growth
+$116M
Cap. Flow
-$176M
Cap. Flow %
-4.93%
Top 10 Hldgs %
45.81%
Holding
127
New
13
Increased
20
Reduced
25
Closed
31

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$79.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$45.9M
3
PCVX icon
Vaxcyte
PCVX
+$45.9M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$39.2M
5
ACRV icon
Acrivon Therapeutics
ACRV
+$38.2M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$158M
2
RLMD icon
Relmada Therapeutics
RLMD
+$88.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$43.3M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$38.4M
5
EW icon
Edwards Lifesciences
EW
+$27.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.34%
2 Financials 0.08%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EW icon
101
Edwards Lifesciences
EW
$52.4B
– –
-330,000
Closed -$27.3M
FULC icon
102
Fulcrum Therapeutics
FULC
$295M
– –
-294,118
Closed -$2.38M
HCAT icon
103
Health Catalyst
HCAT
$119M
– –
-389,962
Closed -$3.78M
HYPR icon
104
Hyperfine
HYPR
$92.2M
– –
-927,388
Closed -$751K
PYXS icon
105
Pyxis Oncology
PYXS
$255M
– –
-1,528,812
Closed -$3.01M
RCUS icon
106
Arcus Biosciences
RCUS
$4.02B
– –
-666,477
Closed -$17.4M
RLMD icon
107
Relmada Therapeutics
RLMD
$490M
– –
-2,383,478
Closed -$88.2M
RVMD icon
108
Revolution Medicines
RVMD
$45.3B
– –
-310,500
Closed -$6.12M
SRZN icon
109
Surrozen
SRZN
$275M
– –
-401
Closed -$12K
WGS icon
110
GeneDx Holdings
WGS
$2.61B
– –
-151,515
Closed -$4.39M
YMAB
111
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-212,018
Closed -$3.06M
NARI
112
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-70,000
Closed -$5.08M
PSTX
113
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
– –
-750,000
Closed -$2.65M
SNCE
114
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
– –
-75,000
Closed -$2.42M
NEPT
115
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
– –
-1,429
Closed -$87K
ICVX
116
DELISTED
Icosavax, Inc. Common Stock
ICVX
– –
-93,591
Closed -$296K
SGEN
117
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-316,544
Closed -$43.3M
SONX
118
DELISTED
Sonendo, Inc.
SONX
– –
-612,204
Closed -$655K
RETA
119
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-100,000
Closed -$2.51M
PRVB
120
DELISTED
Provention Bio, Inc. Common Stock
PRVB
– –
-110,728
Closed -$498K
AGRX
121
DELISTED
Agile Therapeutics
AGRX
– –
-10,647
Closed -$158K
CNCE
122
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-2,150,641
Closed -$14.4M
TCDA
123
PUT
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-500,000
Closed -$5.24M
QTNT
124
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-405,020
Closed -$2.43M
CCXI
125
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-192,680
Closed -$9.95M
2 3 4
5
6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Perceptive Advisors held 127 positions worth $3.56B, up 3.4% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $176M in Q4 2022, closing 31 positions and reducing 25 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $158M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $109M.

  • Perceptive Advisors's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 960,000 shares worth $109M.
  • Perceptive Advisors added most to Sarepta Therapeutics in Q4 2022, an estimated $45.9M increase.
  • Perceptive Advisors's biggest Q4 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $38.4M.
  • Perceptive Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $158M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $3.56B portfolio in Q4 2022.
  • Perceptive Advisors opened 13 new positions and closed 31 in Q4 2022.
  • Perceptive Advisors's portfolio value rose 3.4% quarter-over-quarter to $3.56B.

Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.